ライフサイエンスコーパス: chromogranin A

1 al neuroendocrine distribution of endogenous chromogranin A.

2 onserved N- and C-terminal regions of bovine chromogranin A.

3 gation properties as compared with wild-type chromogranin A.

4 0% of cells, and absence of chymotrypsin and chromogranin A.

5 related peptide, neurotensin, serotonin, and chromogranin A.

6 f chymotrypsin, and rare immunoreactivity to chromogranin A.

7 immunostaining for tau-2, synaptophysin, and chromogranin A.

8 n fragments, and was liberated from purified chromogranin A.

9 o label with antibodies specific for APP and chromogranin A.

10 EVSSKDAAE, which is a degradation product of chromogranin A.

11 g, urinary catecholamines/metanephrines, and chromogranin A.

12 ed 2 neuroendocrine tumor markers, ASCL1 and chromogranin A.

13 of cells expressing the pan-endocrine marker chromogranin A.

14 and neuroendocrine markers synaptophysin and chromogranin A.

15 PA PET/CT results had higher values of serum chromogranin A (100% vs. 20%, P = 0.0003), serotonin, or

16 Among 37 patients with elevated chromogranin A, 26 (70%) achieved normalization or more

17 Synthetic longer (chromogranin A(332-364)) and shorter (chromogranin A(344

18 trometry, a major catestatin form was bovine chromogranin A(332-364); identity of the peptide was con

19 alysis revealed two additional forms: bovine chromogranin A(333-364) and A(343-362).

20 strin (1031 pg/ml; reference value <108) and chromogranin A (337 U/L; reference value <36).

21 omaffin granules, with the major form, human chromogranin A(340-372), bounded by dibasic sites.

22 onger (chromogranin A(332-364)) and shorter (chromogranin A(344-364)) versions of catestatin each inh

23 Serum chromogranin A, a marker for neuroendocrine tumors, is e

24 nase) blocked nicotinic or PMA activation of chromogranin A, although a dominant negative Ras mutant

25 s of the CT pulmonary angiographic findings, chromogranin A and 5-hydroxyindoleacetic acid levels wer

26 Tumor markers (chromogranin A and 5-hydroxyindoleacetic acid) before an

27 levels of oxytocin and peptides derived from chromogranin A and B dramatically decreased in the PC1 K

28 proopiomelanocortin, protachykinins A and B, chromogranin A and B, and secretogranin II.

29 ically abolished regulated secretion of both chromogranin A and beta-endorphin in response to the usu

30 GFI1 colocalizes with chromogranin A and calcitonin-gene-related peptide in em

31 nclude insulin and the two new autoantigens, chromogranin A and islet amyloid polypeptide, all protei

32 Thus, chromogranin A and its catestatin fragment may lie at th

33 a radioimmunoassays showed elevated gastrin, chromogranin A and normal levels of gastrin-releasing pe

34 Staining is negative for chromogranin A and positive for bombesin, serotonin, neu

35 alize with secretory granule markers such as chromogranin A and Rab27b, whereas Myo5c tubules are lab

36 r panendocrine immunohistochemistry markers (chromogranin A and/or synaptophysin); 35% of NETs demons

37 Chromogranins A and B (CGA and CGB) are high capacity, l

38 Chromogranins A and B (CGA and CGB), the major proteins

39 Chromogranins A and B and secretogranin II are a family

40 Chromogranins A and B are high capacity, low affinity ca

41 ch activation, and secretory markers Mucin2, Chromogranin A, and Growth factor-independent 1 (Gfi1) w

42 Different amidation events on chromogranin A, and on peptides processed from proopiome

43 rade [poorly differentiated], respectively), chromogranin A, and proliferation index (Ki-67).

44 Chromogranin A appears to be the most useful serum marke

45 found extensive processing of catestatin in chromogranin A, as judged by catestatin radioimmunoassay

46 in positively for alpha-tubulin, mucins, and chromogranin A, as well as for endoderm transcription fa

47 In summary, common variants in chromogranin A associate with the risk of hypertensive E

48 t express typical LDCV proteins, transfected chromogranins A, B, and brain-derived neurotrophic facto

49 efore probed the role of the MAPK pathway in chromogranin A biosynthesis after secretory stimulation

50 ntestinal enteroendocrine cells positive for chromogranin A, but they had normal numbers of Paneth's,

51 We investigated the effects of a novel chromogranin A catecholamine release-inhibitory fragment

52 t, removing the C-terminal 90 amino acids of chromogranin A caused rerouting to the constitutive secr

53 ratin 20), acinar (chymotrypsin), and islet (chromogranin A) cell markers was performed to analyze th

54 ol as a well-known marker of stress loading, chromogranin A (CgA) and alpha-amylase (AA) are supposed

55 Results showed that proteolytic fragments of chromogranin A (CgA) and chromogranin B (CgB) represent

56 secretory vesicles of neuroendocrine cells, chromogranin A (CGA) and chromogranin B (CGB), have been

57 LDCV formation involves the granin proteins chromogranin A (CgA) and chromogranin B (CgB); CgA- and

58 Chromogranin A (CgA) and neuron-specific enolase (NSE) w

59 Immunohistochemical (IHC) measurement of chromogranin A (CgA) discriminates gastrointestinal (GI)

60 Previously, chromogranin A (CgA) has been shown to play a key role i

61 afficking of the regulated secretory protein chromogranin A (CgA) in PC12 cells.

62 Chromogranin A (CgA) is the major soluble protein in the

63 Chromogranin A (CgA) levels have previously been found t

64 Chromogranin A (CgA) may be critical for secretory granu

65 n active 21-residue peptide derived from the chromogranin A (CgA) precursor, and catestatin is secret

66 ing and organ colonization were inhibited by chromogranin A (CgA), a protein present in variable amou

67 ctors to 125 species and observed that fecal chromogranin A (CgA), a protein secreted by enteroendocr

68 found that physiologic levels of circulating chromogranin A (CgA), a protein secreted by the neuroend

69 stores in which the Ca(2+) storage protein, chromogranin A (CGA), couples with InsP(3)-gated Ca(2+)

70 gnosis is established by elevation of plasma chromogranin A (CgA), serotonin, or urinary 5-hydroxyind

71 r Musashi-1 (Msi-1), neurogenin 3 (NEUROG3), chromogranin A (CgA), serotonin, peptide YY (PYY), oxynt

72 Chromogranin A (CgA), the major soluble protein in catec

73 Chromogranin A (CgA), which binds catecholamines for sto

74 cription of the major vesicular core protein chromogranin A (CgA).

75 secretion in endocrine cells is dependent on chromogranin A (CGA).

76 n, increased tumor grade, and elevated serum chromogranin A (CgA).

77 cells, we show that SgIII is complexed with Chromogranin A (CgA).

78 e neuroendocrine (NE) markers calcitonin and chromogranin A (CgA).

79 the N- and C-terminal regions of circulating chromogranin A (CgA, CHGA), classically an antiangiogeni

80 Chromogranin A (CHGA) and its derived peptides, which ar

81 es, we have identified the peptide WE14 from chromogranin A (ChgA) as the antigen for highly diabetog

82 Chromogranin A (ChgA) has been identified as the antigen

83 Recent studies suggest an important role of chromogranin A (CHGA) in the regulated secretory pathway

84 Chromogranin A (ChgA) is an autoantigen for CD4(+) T cel

85 The acidic glycoprotein chromogranin A (CHGA) is co-stored/co-secreted with cate

86 Chromogranin A (CHGA) is coreleased with catecholamines

87 The secretory pro-hormone chromogranin A (CHGA) is densely packed into storage gra

88 The secretory prohormone chromogranin A (CHGA) is overexpressed in essential hype

89 etermine whether the common variation at the chromogranin A (CHGA) locus increases susceptibility to

90 Whether chromogranin A (CHGA) polymorphisms predict end-organ co

91 Chromogranin A (CHGA) regulates catecholamine storage an

92 Chromogranin A (CHGA) regulates the storage and release

93 Chromogranin A (CHGA) triggers catecholamine secretory g

94 Chromogranin A (CHGA), a protein released from secretory

95 mine release inhibitory peptide derived from chromogranin A (CHGA), and other CHGA- or chromogranin B

96 ied the beta cell secretory granule protein, chromogranin A (ChgA), as a new autoantigen in type 1 di

97 tide derived from the neuroendocrine protein chromogranin A (CHGA), is a functional AMP and is presen

98 Chromogranin A (Chga), which catalyzes formation and car

99 Catestatin (CST), a chromogranin A (CHGA)-derived peptide, is a potent inhib

100 Chromogranin A (CHGA/Chga), a proprotein, widely distrib

101 esicular monoamine transporter (VMAT1,2) and chromogranin A (ChrgA), are also expressed in taste buds

102 Chromogranin A, chromogranin B, and secretogranin II, me

103 ocortin (POMC), provasopressin, prooxytocin, chromogranin A, chromogranin B, and secretogranin II.

104 ells revealed reciprocal changes in secreted chromogranin A COOH-terminal fragments (increased approx

105 Chromogranin A, coreleased with catecholamines by exocyt

106 Point mutations of the chromogranin A CRE suggested that this element was neces

107 Here, we probed the role of the chromogranin A-derived peptide pancreastatin (PST: CHGA(

108 Pancreastatin (PST), a chromogranin A-derived peptide, is a potent physiologica

109 orms of gastrin in each, and pyloric mucosal chromogranin A-derived peptides were investigated in the

110 nces in the concentration of pyloric mucosal chromogranin A-derived peptides were recorded between in

111 d secretion in both neuroendocrine cells and chromogranin A-expressing COS7 cells used as a simplifie

112 Both the MAPK pathway and chromogranin A expression may be activated by cytosolic

113 Serum markers include chromogranin A for neuroendocrine tumors, pepsinogen I f

114 tely 71 and approximately 27 kD NH2-terminal chromogranin A fragments.

115 PACAP activated the endogenous chromogranin A gene by four- to fivefold.

116 IGF-I stimulated chromogranin A gene expression by Northern blot analysis

117 led with assay of histidine decarboxylase or chromogranin A gene expression is useful in the assessme

118 ed whether PACAP regulates expression of the chromogranin A gene in PC12 rat chromaffin cells, so as

119 in, performance status, tumor burden, plasma chromogranin A (>/=600 mug/L), neuron-specific enolase (

120 Tissue morphology, abundance of chromogranin A, gut hormones, alpha-defensin, mucin 2, N

121 Chromogranin A immunoblots revealed chromogranin A proce

122 tion was used to analyze the distribution of chromogranin A immunoreactive cells in serial sections o

123 injection, total insulin content and insulin:chromogranin A immunoreactivity were reduced by approxim

124 hemistry demonstrated a relative decrease of chromogranin A in processes (where regulated secretory v

125 retory granules, and stimulated secretion of chromogranin A increased 50%.

126 imulation of secretion in catecholamines and chromogranin A, indicating that secretion of solAPPcyt w

127 cells did not express defensin-5, Muc-2, or chromogranin A, indicating that they were not lineage co

128 Specific endopeptidases cleave chromogranin A into biologically active peptide fragment

129 These results demonstrate that chromogranin A is a substrate for the endogenous endopro

130 The catestatin fragment of chromogranin A is an endogenous inhibitor of nicotinic c

131 The catestatin fragment of chromogranin A is an inhibitor of catecholamine release,

132 This region of chromogranin A is extensively processed within chromaffi

133 Chromogranin A is released together with epinephrine and

134 Since chromogranin A is secreted along with catecholamines, we

135 Chromogranin A is the major soluble core component in se

136 Chromogranin A knock-out (Chga-KO) mice display increase

137 Chromogranin A knockout (Chga-KO) mice exhibit enhanced

138 ng a greater than 50% reduction in the nadir chromogranin A level within the 1st year after treatment

139 estimated absorbed BM dose, elevated plasma chromogranin A level, baseline blood counts, and renal f

140 Chromogranin A levels were significantly higher in both

141 rmal, as were 5-hydroxyindoleacetic acid and chromogranin A levels.

142 on of PCl suggests that the action of PC1 on chromogranin A may be specific within the chromogranin/s

143 and calcitonin and suggest that the role of chromogranin A may be to stabilize an otherwise unstable

144 This small domain within chromogranin A may contribute to a novel, autocrine, hom

145 owledge of cleavage sites of catestatin from chromogranin A may provide a useful starting point in an

146 function, e.g., histidine decarboxylase and chromogranin A messenger RNA abundance, in carcinoid tum

147 NH2-terminal fragment as well as the parent chromogranin A molecule accumulated, while an approximat

148 eprazole, VMAT2, histidine decarboxylase and chromogranin A mRNA abundance in gastric corpus, and pla

149 Chromogranin A mRNA responded to MAPK pathway manipulati

150 Chromogranin A mRNA showed a time-dependent 3.87-fold re

151 ng for mucosal 5-HT synthesis; P < 0.01] and chromogranin A (neuroendocrine secretion; P < 0.01), wit

152 The baseline levels of chromogranin A, neuron-specific enolase, and multiple so

153 We also measured fasting serum chromogranin A, neuron-specific enolase, gastrin, glucag

154 Elevated baseline chromogranin A, neuron-specific enolase, placental growt

155 n L-DsRed fusion protein with enkephalin and chromogranin A neuropeptides that are present in secreto

156 isense PC1 induction, an approximately 66-kD chromogranin A NH2-terminal fragment as well as the pare

157 hetic peptides spanning approximately 80% of chromogranin A, one (bovine chromogranin A344-364 [RSMRL

158 and neuroendocrine markers synaptophysin and chromogranin A (P < 0.0000001).

159 as predominantly localized to epithelial and chromogranin A-positive endocrine cells.

160 et cell function while negatively regulating chromogranin A-positive enteroendocrine cell number.

161 otyping, including catecholamine production, chromogranin A precursor, and its catestatin product.

162 Chromogranin A immunoblots revealed chromogranin A processing, from both the NH2 and COOH te

163 A series of chromogranin A promoter 5' deletion mutant/luciferase re

164 markedly diminished trans-activation of the chromogranin A promoter by PACAP.

165 r was in linkage disequilibrium with 1 major Chromogranin A promoter haplotype, although promoter hap

166 cis, activation by the cascade maps onto the chromogranin A promoter proximal CRE, which is both nece

167 , and calcium-dependent signals map onto the chromogranin A promoter proximal CRE.

168 oximal CRE box is entirely necessary for the chromogranin A promoter response to PACAP.

169 kinase blocked the response of a transfected chromogranin A promoter to nicotine or protein kinase C

170 antagonist KCREB blocked the response of the chromogranin A promoter to nicotine, cAMP, or MAPK pathw

171 protein kinase C mapped principally onto the chromogranin A promoter's cAMP response element (TGACGTA

172 ltimately relays the secretory signal to the chromogranin A promoter's CRE box in cis.

173 tion in a fashion similar to the transfected chromogranin A promoter, in both direction and magnitude

174 n enhanced basal as well as IGF-I-stimulated chromogranin A promoter.

175 fection of pathway components stimulated the chromogranin A promoter.

176 we employed a novel mouse strain harboring a chromogranin A promoter/firefly luciferase reporter tran

177 e obtained with a transfected 1,200-bp mouse chromogranin A promoter/luciferase reporter construct.

178 Transfected chromogranin A promoter/luciferase reporter constructs w

179 edistribution of desmoplakin, keratin 5, and chromogranin A proteins.

180 istochemistry for cytokeratins 7 and 20, and Chromogranin A-proteins which have a well described expr

181 his peptide blocked the inhibitory effect of chromogranin A proteolytic fragments on nicotinic-stimul

182 differentiation of thymocytes expressing the chromogranin A-reactive BDC-2.5 and BDC-10.1 TCRs or the

183 atecholamine release, and was shared by this chromogranin A region from several species.

184 ced secretion, transcriptional activation of chromogranin A remained unaltered.

185 gen receptor, prostate specific antigen, and chromogranin A, respectively.

186 as associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic r

187 sphatase and the regulated secretory protein chromogranin A resulted in an increased chromogranin sto

188 and-Factor[rs12829220] in the control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vit

189 Plasma cortisol and chromogranin A showed a significant association that did

190 The frequencies of islet Ag-reactive chromogranin A-specific CD4(+) T cells and islet specifi

191 marker MTA1, the apoptotic marker NALP, and chromogranin A) that define gut neuroendocrine cell beha

192 biosynthesis of the major secreted protein (chromogranin A), that the activation is transcriptional,

193 secretion also activates the biosynthesis of chromogranin A, the major protein released with catechol

194 lls, we studied the biosynthetic response of chromogranin A, the major soluble protein co-stored and

195 Such coupling triggers the biosynthesis of chromogranin A, the precursor of catestatin.

196 ynthesis of just released catecholamines and chromogranin A, the precursor of the catecholamine relea

197 ization domain did not affect the sorting of chromogranin A to the regulated secretory pathway.

198 Thus, PACAP-evoked chromogranin A transcription and catecholamine secretion

199 -binding protein CREB, blunted activation of chromogranin A transcription by nicotine, phorbol ester,

200 We conclude that activation of chromogranin A transcription by secretory stimulation in

201 receptor antagonist PACAP6-38 impaired both chromogranin A transcription or catecholamine secretion

202 Therefore, we propose that PACAP signals to chromogranin A transcription through the CRE in cis, and

203 bited both forskolin and PACAP activation of chromogranin A transcription, revealing that PACAP-induc

204 timuli influence exocytotic secretion versus chromogranin A transcription.

205 Chromogranin A was identified as a promising marker for

206 a new phosphorylation site (S191) in bovine chromogranin A was identified.

207 eporter and the neuroendocrine-specific gene chromogranin A was induced 2-3.3-fold by insulin-like gr